{"doi":"10.1016/j.jgar.2019.08.010","title":"Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety","abstract":null,"journal":"Journal of Global Antimicrobial Resistance","year":2020,"id":630161,"datarank":0.5333022092234121,"base_score":3.5553480614894135,"endowment":3.5553480614894135,"self_citation_contribution":0.5333022092234121,"citation_network_contribution":0.0,"self_endowment_contribution":0.5333022092234121,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":34,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1233257,"name":"Carlo Federico Perno","orcid":"0000-0002-0825-5388","position":1,"is_corresponding":false},{"id":1632389,"name":"Valeria Cento","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Lara + Coto: visión d'un Berlín creativu","abstract":"The results available so far support dolutegravir-based 2DRs as excellent treatment options for adults with HIV-1 infection, either naïve or already virologically suppressed on their current antiretroviral regimen.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"31446092","pmcid":null,"openalex_id":"https://openalex.org/W31446092","authors":[],"funders":[{"funder_name":"Janssen,","grant_id":"","title":null},{"funder_name":"Abbvie,","grant_id":"","title":null},{"funder_name":"Gilead,","grant_id":"","title":null},{"funder_name":"Merck and","grant_id":"","title":null},{"funder_name":"Theratechnologies,","grant_id":"","title":null},{"funder_name":"ViiV,","grant_id":"","title":null}],"total_grants":6,"fwci":0.0,"citation_percentile":0.00886988,"influential_citations":0,"citation_trend":[],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://www.sciencedirect.com/science/article/pii/S2213716519302085/pdf","host_type":"publisher"},{"url":"https://dialnet.unirioja.es/servlet/articulo?codigo=3607452","host_type":"journal"},{"url":"https://zenodo.org/record/37062","host_type":"repository"},{"url":"https://doaj.org/article/4faed53999bf460da1b9b4ae21bc9f51","host_type":"repository"}],"fields_of_study":["Spanish Culture and Identity"],"mesh_terms":["Humans","HIV Infections","Oxazines","Piperazines","Pyridones","Heterocyclic Compounds, 3-Ring","Lamivudine","Reverse Transcriptase Inhibitors","Anti-HIV Agents","Drug Therapy, Combination","Clinical Trials as Topic","Rilpivirine","Sustained Virologic Response","Equivalence Trials as Topic","Dolutegravir"],"keywords":["Art","HIV-1","Dual Therapy","Dolutegravir","Integrase Resistance","Residual Viraemia","Treatment Simplification"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T20:35:53.929889Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}